Nivolumab
Monoclonal antibody
Also known as ONO-4538
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Colorectal Cancer, Advanced Metastatic Colorectal Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (6)
- Opdivo, in combination with doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL)
- Malignant Pleural Mesothelioma OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
- Classical Hodgkin lymphoma (cHL): adult and pediatric (12 years and older) patients with previously untreated Stage III or IV cHL in combination with doxorubicin, vinblastine, and dacarbazine; adults with cHL that has relapsed or progressed after autologous HSCT and brentuximab vedotin, or after 3 or more lines of systemic therapy that includes autologous HSCT
- Adjuvant treatment of adults with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT)
- Opdivo (nivolumab): initial indication advanced melanoma; later extended to NSCLC and other cancers
- Unresectable melanoma (first approval worldwide of a PD-1 checkpoint inhibitor; Ono Pharmaceutical)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
CheckMate057 NCT01673867 · Non-Squamous Cell Non-small Cell Lung Cancer This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence. Registry: NCT01673867 | 3 | Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)) 2015-02-05 | Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) | Partial signal | link ↗ |
View 5 more trials
NCT01642004 NCT01642004 · Squamous Cell Non-small Cell Lung Cancer Participants were randomized to nivolumab or active docetaxel treatment, with 135 and 137 participants in the respective groups, but the trial was open-label rather than blinded. The primary overall-survival comparison favored nivolumab and was statistically significant, although the lack of blinding limits the strength of the evidence. Registry: NCT01642004 | 3 | Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months); Overall Survival (OS) Rate in All Randomized Participants (Randomization to 18 months post-randomization, up to June 2015); Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months) 2014-11-17 | Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33) | Partial signal | link ↗ |
CheckMate 816 NCT02998528 · Non-Small Cell Lung Cancer The trial randomized 505 participants and compared nivolumab plus chemotherapy with chemotherapy alone, but treatment assignment was not blinded; the primary efficacy comparison included 179 participants per arm. Both primary endpoints were favorable and statistically significant—event-free survival and pathologic complete response—yet the open-label design and absence of a reported power calculation limit the strength of the evidence. Registry: NCT02998528 | 3 | Event-Free Survival (EFS) (From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)); Pathologic Complete Response (pCR) Rate (From randomization up to a median of 30 months after randomization.) 2021-09-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT04025879 NCT04025879 · Non-Small Cell Lung Cancer Patients were randomized to nivolumab or a matching placebo on top of chemotherapy, with patients and investigators blinded, and the primary endpoint, event-free survival judged by blinded independent central review, was clearly met (hazard ratio 0.58, p=0.00025). The protocol reports a sample-size calculation for this endpoint requiring about 452 randomized patients, and 461 were enrolled. Registry: NCT04025879 | 3 | Event-Free Survival (EFS) by BICR (From randomization to disease progression, worsening, recurrence, or death due to any cause (up to approximately 44 months)) 2023-07-26 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
CheckMate 227 NCT02477826 · Non-Small Cell Lung Cancer Patients were randomly assigned to nivolumab-based treatment or chemotherapy, with survival and independently reviewed progression as primary endpoints, but the trial was open-label. The primary comparisons pointed in different directions: several combination comparisons favoured nivolumab, while nivolumab alone versus chemotherapy, and overall survival in Part 3, showed no clear difference. Registry: NCT02477826 | 3 | Progression-Free Survival Per BICR (From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)); Overall Survival (From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)) 2024-10-25 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
CheckMate 9LA NCT03215706 · Non-Small Cell Lung Cancer The trial was randomized and active-controlled but open-label, enrolling 719 participants; its primary endpoint, overall survival, was an objective clinical outcome and was statistically significantly better with nivolumab plus ipilimumab and chemotherapy than with chemotherapy alone. The open-label design and absence of a reported power calculation limit the strength of the evidence despite the positive survival result. Registry: NCT03215706 | 3 | Overall Survival (OS) (From date of randomization to date of death (assessed up to October 2019, approximately 23 months)) 2019-08-16 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (126)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (734)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (297)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (393)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (24)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (40)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Appears in other studies (37)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Opdivo Qvantig, Pembrolizumab, Pembrolizumab berahyaluronidase alfa and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nivolumab: this drug | Approved | Monoclonal antibody | PD-1 | Weak signal | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Encorafenib | Approved | Small molecule | BRAF V600E | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Approved | Small molecule | VEGFR1/2/3 | Reliable signal | NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001 | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7) | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016) | |
| Sotorasib | Approved | Small molecule | KRAS G12C | not yet graded | No reviewed efficacy summary in this indication | |
| Tucatinib | Approved | Small molecule | HER2 | Partial signal | NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Telisotuzumab Adizutecan | Phase 3 | Antibody–drug conjugate | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Bafisontamab | Phase 2 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Pelareorep | Phase 2 | Oncolytic virus | Tumor cells (oncolytic replication) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(383 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Nivolumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (46)
November 2026 (5)
What to watch
What to watch
What to watch
What to watch
December 2026 (41)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (175)
January 2027 (15)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (14)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
March 2027 (17)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2027 (17)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
May 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (21)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (14)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
September 2027 (12)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
October 2027 (14)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
November 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
December 2027 (25)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (61)
January 2028 (6)
What to watch
What to watch
What to watch
What to watch
February 2028 (4)
What to watch
What to watch
What to watch
What to watch
March 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2028 (4)
What to watch
What to watch
What to watch
May 2028 (2)
What to watch
What to watch
June 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2028 (6)
What to watch
What to watch
What to watch
August 2028 (3)
What to watch
What to watch
What to watch
September 2028 (2)
What to watch
What to watch
October 2028 (3)
What to watch
What to watch
What to watch
November 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
December 2028 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (40)
January 2029 (3)
What to watch
What to watch
What to watch
February 2029 (2)
March 2029 (4)
What to watch
What to watch
What to watch
April 2029 (4)
What to watch
What to watch
What to watch
What to watch
May 2029 (4)
What to watch
What to watch
What to watch
June 2029 (3)
What to watch
What to watch
July 2029 (4)
What to watch
What to watch
What to watch
August 2029 (5)
What to watch
What to watch
What to watch
What to watch
September 2029 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
October 2029 (2)
November 2029 (2)
December 2029 (1)
What to watch
2030 (34)
January 2030 (4)
What to watch
What to watch
What to watch
March 2030 (3)
What to watch
What to watch
What to watch
April 2030 (2)
May 2030 (1)
What to watch
June 2030 (1)
What to watch
July 2030 (1)
What to watch
August 2030 (1)
September 2030 (4)
October 2030 (4)
What to watch
What to watch
What to watch
November 2030 (1)
What to watch
December 2030 (12)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2031 (13)
January 2031 (1)
What to watch
February 2031 (2)
April 2031 (2)
August 2031 (3)
What to watch
What to watch
What to watch
September 2031 (2)
What to watch
What to watch
October 2031 (1)
What to watch
2032 (9)
January 2032 (1)
What to watch
February 2032 (1)
What to watch
March 2032 (1)
What to watch
April 2032 (2)
May 2032 (2)
July 2032 (2)
What to watch
What to watch
2033 (3)
March 2033 (1)
What to watch
June 2033 (1)
What to watch
August 2033 (1)
What to watch
2034 (1)
April 2034 (1)
What to watch
2040 (1)
February 2040 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent